Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade.
| dc.contributor.author | Valpione, Sara | |
| dc.contributor.author | Pasquali, S | |
| dc.contributor.author | Campana, L | |
| dc.contributor.author | Piccin, L | |
| dc.contributor.author | Mocellin, S | |
| dc.contributor.author | Pigozzo, J | |
| dc.contributor.author | Chiarion-Sileni, V | |
| dc.date.accessioned | 2018-05-13T19:27:12Z | |
| dc.date.available | 2018-05-13T19:27:12Z | |
| dc.date.issued | 2018-04-11 | |
| dc.identifier.citation | Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade. 2018, 16(1): 94 J Transl Med | en |
| dc.identifier.issn | 1479-5876 | |
| dc.identifier.pmid | 29642948 | |
| dc.identifier.doi | 10.1186/s12967-018-1467-x | |
| dc.identifier.uri | http://hdl.handle.net/10541/621000 | |
| dc.description.abstract | Ipilimumab is a licensed immunotherapy for metastatic melanoma patients and, in the US, as adjuvant treatment for high risk melanoma radically resected. The use of ipilimumab is associated with a typical but unpredictable pattern of side effects. The purpose of this study was to identify clinical features and blood biomarkers capable of predicting ipilimumab related toxicity. | |
| dc.language.iso | en | en |
| dc.rights | Archived with thanks to Journal of translational medicine | en |
| dc.title | Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade. | en |
| dc.type | Article | en |
| dc.contributor.department | CRUK Manchester Institute and The Christie NHS Foundation Trust, The University of Manchester, Manchester, M20 4GJ | en |
| dc.identifier.journal | Journal of Translational Medicine | en |
| refterms.dateFOA | 2018-12-17T15:22:01Z | |
| html.description.abstract | Ipilimumab is a licensed immunotherapy for metastatic melanoma patients and, in the US, as adjuvant treatment for high risk melanoma radically resected. The use of ipilimumab is associated with a typical but unpredictable pattern of side effects. The purpose of this study was to identify clinical features and blood biomarkers capable of predicting ipilimumab related toxicity. |
